TNFSF10 and Miyoshi myopathy: We proved in vitro the therapeutic benefits of embedding NKs with WJ-MSCs in a fibrin scaffold for the treatment of MBD and their synergistic therapeutic effect when combined with bortezomib (BZ), a first-line approved proteasome inhibitor agent for the treatment of MM, and tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL), a potent cytotoxic agent that selectively induces anti-tumor effect.